A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE‐BC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE‐BC

Published:2022-01-19 Issue:8 Volume:128 Page:1692-1698
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Matsuura Kazuo¹,Tsurutani Junji²,Inoue Kenichi³,Tanabe Yuko⁴,Taira Tetsuhiko⁵,Kubota Kaoru⁶,Tamura Tomohide⁷,Saeki Toshiaki¹^ORCID

Affiliation:

1. Department of Breast Oncology Saitama Medical University International Medical Center Saitama Japan

2. Advanced Cancer Translational Research Institute Showa University Tokyo Japan

3. Department of Breast Oncology Saitama Cancer Center Saitama Japan

4. Department of Medical Oncology Toranomon Hospital Tokyo Japan

5. Department of Medical Oncology Sagara Hospital Kagoshima Japan

6. Department of Pulmonary Medicine and Oncology Graduate School of Medicine Nippon Medical School Tokyo Japan

7. Thoracic Center St. Luke's International Hospital Tokyo Japan

Funder

Taiho Pharmaceutical

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34088

Reference20 articles.

1. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

2. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

3. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis

4. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study;The Oncologist;2024-09-11

2. Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis;Frontiers in Oncology;2024-07-26

3. Comparing the Efficacy of Fosnetupitant, an NK<sub>1</sub> Receptor Antagonist in CDDP-Based Regimens, with That of Fosaprepitant and Aprepitant: A Retrospective Observational Study;Biological and Pharmaceutical Bulletin;2024-03-25

4. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting;ESMO Open;2024-02

5. Comparing Injection Site Reactions of Aprepitant and Fosaprepitant in Gynecologic Cancer Chemotherapy;In Vivo;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3